Risk Factors Associated with Group B Streptococcus Resistant to Clindamycin and Erythromycin in Pregnant Korean Women
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: The prevalence of group B streptococcus (GBS) among pregnant women and neonates in the Republic of Korea has increased. In addition, rates of resistance to antibiotics recommended for pregnant women allergic to penicillin, such as clindamycin and erythromycin, have increased. The aim of this study was to evaluate subject characteristics associated with GBS resistance to clindamycin and erythromycin. Materials and Methods: A total of 418 clinical isolates from pregnant women in Korea were screened for antibiotic resistance from January 2006 to December 2011. Sociodemographic information, medical and obstetric history, and details of events during the previous 2 weeks were recorded using a standardized questionnaire. Results: The resistance rates were 39.5% for clindamycin and 23.0% for erythromycin. In multiple logistic regression analysis, the subject characteristic significantly associated with resistance to both antibiotics was a history of symptomatic sore throat in the 2weeks before obtaining the specimen (erythromycin: odds ratio [OR]: 2.13, 95% confidence interval [CI]: 1.10 to 4.13; clindamycin:OR: 2.31, 95% CI: 1.21, 4.42). Premature rupture of membranes (PROM) had an association of borderline significance. Conclusions: In the urgent treatment of GBS-colonized pregnant women, the subject’s history of previous sore throat and PROM should be considered when choosing appropriate antibiotics.
Abstract
Background: The prevalence of group B streptococcus (GBS) among pregnant women and neonates in the Republic of Korea has increased. In addition, rates of resistance to antibiotics recommended for pregnant women allergic to penicillin, such as clindamycin and erythromycin, have increased. The aim of this study was to evaluate subject characteristics associated with GBS resistance to clindamycin and erythromycin. Materials and Methods: A total of 418 clinical isolates from pregnant women in Korea were screened for antibiotic resistance from January 2006 to December 2011. Sociodemographic information, medical and obstetric history, and details of events during the previous 2 weeks were recorded using a standardized questionnaire. Results: The resistance rates were 39.5% for clindamycin and 23.0% for erythromycin. In multiple logistic regression analysis, the subject characteristic significantly associated with resistance to both antibiotics was a history of symptomatic sore throat in the 2weeks before obtaining the specimen (erythromycin: odds ratio [OR]: 2.13, 95% confidence interval [CI]: 1.10 to 4.13; clindamycin:OR: 2.31, 95% CI: 1.21, 4.42). Premature rupture of membranes (PROM) had an association of borderline significance. Conclusions: In the urgent treatment of GBS-colonized pregnant women, the subject’s history of previous sore throat and PROM should be considered when choosing appropriate antibiotics.
참고문헌 (27)
- Baker CJ, "Transmission of group B streptococciamong parturient women and their neonates", J Pediatr, 83, pp.919~925 (1973)
- Yoon HK, "A case of neonatal group B streptococcal meningitis", JKorean Pediatr Soc, 27, pp.1011~1017 (1984)
- Uh Y, "Colonizationrate of group B Streptococcus in pregnant women andneonates", Korean J Clin Pathol, 14, pp.447~453 (1994)
- Schrag S, "Preventionof perinatal group B streptococcal disease. Revisedguidelines from CDC", MMWR Recomm Rep, 51, pp.1~22 (2002)
- Uh Y, "Colonizationrates and serotypes of group B streptococci isolatedfrom pregnant women in a Korean tertiary hospital", Eur J Clin Microbiol Infect Dis, 16, pp.753~756 (1997)
- 김민우, "우리나라 임신부에서의 B군 사슬알균의집락화에 대한 연구", Obstetrics & Gynecology Science, 49(2), pp.337~344 (2006), 대한산부인과학회
- Choi KU, "Clinical significance of group B streptococcal infectionin pregnant women", Korean J Obstet Gynecol, 45, pp.811~815 (2002)
- Lee BK, "Epidemiology ofgroup B streptococcus in Korean pregnant women", EpidemiolInfect, 138, pp.292~298 (2010)
- Schrag SJ, "Group B streptococcal disease in the era ofintrapartum antibiotic prophylaxis", N Engl J Med, 342, pp.15~20 (2000)
- Berardi A, "Group B streptococcus and preventive strategiesin Europe", Arch Dis Child Fetal Neonatal Ed, 93, pp.F249~ (2008)
- Betriu C, "Erythromycin andclindamycin resistance and telithromycin susceptibilityin Streptococcus agalactiae", Antimicrob Agents Chemother, 47, pp.1112~1114 (2003)
- Arisoy AS, "Maternal carriage and antimicrobial resistance profile of group B Streptococcus", Infection, 31, pp.244~246 (2003)
- Pearlman MD, "Frequent resistanceof clinical group B streptococci isolates to clindamycinand erythromycin", Obstet Gynecol, 92, pp.258~261 (1998)
- Lin FY, "Antibiotic susceptibility profiles forgroup B streptococci isolated from neonates, 1995-1998", Clin Infect Dis, 31, pp.76~79 (2000)
- Manning SD, "Correlates of antibiotic-resistantgroup B streptococcus isolated from pregnant women", Obstet Gynecol, 101, pp.74~79 (2003)
- 어영, "Correlation of Serotypes and Genotypes of Macrolide-Resistant Streptococcus agalactiae", Yonsei Medical Journal, 46(4), pp.480~483 (2005), 연세대학교의과대학
- 서용수, "Changing Molecular Epidemiology of Group B Streptococcus in Korea", Journal of Korean Medical Science, 25(6), pp.817~823 (2010), 대한의학회
- NCCLS, "Performance standards for antimicrobial susceptibilitytesting. Twelfth informational supplement. NCCLS document M100-S12", NCCLS, ~ (2002)
- Anonymous, "Prevention of perinatal group B streptococcaldisease: a public health perspective. Centers for DiseaseControl and Prevention", MMWR Recomm Rep, 45, pp.1~24 (1996)
- Verani JR, "Division of Bacterial Diseases,National Center for Immunization and RespiratoryDiseases, Centers for Disease Control and Prevention(CDC). Prevention of perinatal group B streptococcaldisease--revised guidelines from CDC, 2010", MMWR RecommRep, 59, pp.1~36 (2010)
- Gygax SE, "Erythromycin and clindamycin resistancein group B streptococcal clinical isolates", AntimicrobAgents Chemother, 50, pp.1875~1877 (2006)
- Desjardins M, "Prevalence and mechanisms of erythromycin resistancein group A and group B Streptococcus: implicationsfor reporting susceptibility results", J Clin Microbiol, 42, pp.5620~5623 (2004)
- Schoening TE, "Prevalence of erythromycinand clindamycin resistance among Streptococcusagalactiae isolates in Germany", Clin Microbiol Infect, 11, pp.579~582 (2005)
- Hoban DJ, "Worldwide prevalence of antimicrobial resistancein Streptococcus pneumoniae, Haemophilus influenzae,and Moraxella catarrhalis in the SENTRY AntimicrobialSurveillance Program, 1997-1999", Clin Infect Dis, 32(2), pp.S81~S93 (2001)
- Colodner R, "Risk factorsfor community-acquired urinary tract infection due toquinolone-resistant E", coli. Infection, 36, pp.41~45 (2008)
- Arslan H, "UrinaryTract Infection Study Group. Risk factors for ciprofloxacinresistance among Escherichia coli strains isolatedfrom community-acquired urinary tract infections inTurkey", J Antimicrob Chemother, 56, pp.914~918 (2005)
- Kim EJ, "Risk factors for group B streptococcuscolonization among pregnant women in Korea", EpidemiolHealth, 33, pp.e2011010~ (2011)